Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Nuvectis Pharma (NVCT) Return on Equity (2021 - 2026)

Nuvectis Pharma has reported Return on Equity over the past 6 years, most recently at 0.02% for Q1 2026.

  • Quarterly results put Return on Equity at 0.02% for Q1 2026, changed 0.0% from a year ago — trailing twelve months through Mar 2026 was 0.02% (changed 0.0% YoY), and the annual figure for FY2025 was 0.02%, changed 0.0%.
  • Return on Equity reached 0.02% in Q1 2026 per NVCT's latest filing, down from 0.01% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.01% in Q3 2022 and bottomed at 0.09% in Q1 2022.
  • Median Return on Equity over the past 5 years was 0.01% (2023), compared with a mean of 0.02%.
  • The largest annual shift saw Return on Equity fell -2bps in 2022 before it increased 7bps in 2023.
  • Over 5 years, Return on Equity stood at 0.01% in 2022, then crashed by -40bps to 0.02% in 2023, then fell by -19bps to 0.02% in 2024, then soared by 32bps to 0.01% in 2025, then tumbled by -34bps to 0.02% in 2026.
  • Business Quant data shows Return on Equity for NVCT at 0.02% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.